Medicamen Biotech Limited has entered into a long-term Manufacturing & Supply Agreement with a prominent pharmaceutical distributor and marketing company operating in the US and European markets. The agreement, spanning 10 years, aims to leverage Medicamen’s USFDA-approved Oncology Unit for contract manufacturing.
As part of the deal, Medicamen Biotech will produce pharmaceutical products tailored to the technical specifications of its US-based partner. The agreement ensures a 25% upfront payment upon signing, securing financial stability for future operations.
The collaboration is expected to enhance Medicamen’s presence in international markets, utilizing its expertise in manufacturing and process R&D to provide value-added custom manufacturing services. The company emphasized that this agreement is not a related-party transaction, ensuring compliance with regulatory norms.
This strategic move aligns with Medicamen Biotech’s global expansion plans, strengthening its foothold in the highly competitive US and European pharmaceutical sectors.
